cf revenu de-risk
pipelin rais pt
recent approv drug trikafta strong earli launch metric
de-risk cf revenu view expect pipelin
evolv poc data anticip across multipl asset
expect provid confid investor potenti diversifi
beyond cf new pt reflect confid de-risk cf
revenu discount rate vs previous valu pipelin
probabl peak opportun aatd
report strong top-line bottom-lin beat
guidanc impli yoy top-line growth report
strong top-line beat vs con
vs con result primarili driven better-than-expect
trikafta launch approv octob us vs
con compani guidanc product revenu
indic yoy growth impli continu strong uptak
trikafta view result de-risk vrtx cf revenu stream
believ semin year multipl pipelin catalyst
year see updat model result
guidanc new pt reflect confid de-risk
cf revenu discount rate vs previous valu pipelin
probabl peak opportun aatd
trikafta approv us recent reimburs agreement
drug major territori de-risk cf revenu stream view
recent approv launch trikafta strengthen vrtx posit
domin leader cf drug approv
age trial underway patient estim elig
drug recent reimburs agreement sever vrtx cf
drug note trikafta approv ex-u major territori includ
eu uk spain australia remov key overhang stock
consequ believ cf revenu significantli de-risk
reflect model discount rate versu previous
current level believ major cf opportun bake
stock
expect pipelin emerg highlight key catalyst
next month investor believ cf opportun
tr target
bake stock current level see semin year pipelin clariti
expect see data trial aatd data patient sickl cell beta-
thalassemia trial collabor crsp poc data like fsg
renal diseas data clariti pain program potenti global partnership pain
trial type diabet investig potenti cur cellular therapi semma therapeut
recent acquisit initi late current assign probabl
peak opportun aatd contribut dcf think pipelin could
multi-billion dollar opportun view even one two asset success
pipelin valu assign fair represent
investor question whether potenti beat rais talk manag
learn guidanc provid account growth new het-min patient trikafta
increas revenu convers due higher trikafta price manag also note
impact cf center capac impact us highlight factor could
potenti impact beat guidanc faster expect convers rapid adopt
trikafta het-min patient better expect persist complianc especi
patient convert orkambi also note compani histor guid conserv
begin year
model major cf patient treat cf drug assum convers
trikafta talk manag learn convers trikafta seen
patient cf drug symdeko patient led convers howev note trikafta
superior product profil anticip convers major patient trikafta
time model major patient convert trikafta also updat
model reflect across cf drug us
page
strh research compani report updat
page
incom statement figur million except per share franchisecyst fibrosi franchiseww kalydeco sale orkambi sale symdeko sale trikafta sale cf franchis sale corrector deficiencyprob corrector us corrector row sale corrector defici sale corrector defici revenu product rev total product total total vertex guid incom margin interest incom fv deriv incom expens tax rate incom ep ep non- except ep fc consensu jan stock option exp incom ep ep share count share count vertex pharmaceut incorpor
inc engag busi discov develop manufactur
commerci small molecul drug patient seriou diseas focus develop
commerci therapi treatment cystic fibrosi infecti diseas includ viral
infect influenza bacteri infect autoimmun diseas rheumatoid
arthriti cancer inflammatori bowel diseas neurolog disord includ pain multipl
sclerosi compani found joshua boger headquart boston
rate buy see continu growth due greater uptak cf cystic fibrosi patient
follow recent approv trikafta potenti could treat cf patient
recent reimburs agreement major territori includ eu uk spain australia franc
canada remain outstand key overhang stock potenti price upsid
current model symdeko price trikafta ex-u territori premium symdeko
trikafta ex-u see upsid also one highest growth compani
biopharma ep compound-annual-growth-rate consensu versu biotech large-cap
mean ex-bmrn us pharma mean challeng market predict growth
compani may perform better view final potenti global pain partnership non-
oipiod pain drug would upsid model
valuat risk
use dcf arriv pt use discount rate appropri lower-risk larg
cap compani yet diversifi use termin valu believ compani use
capit continu gener revenu assign probabl peak opportun aatd
risk poor uptak reimburs trikafta clinic trial failur lack binari event catalyst
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
